Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level

Journal of Clinical Oncology

Volumn 24, Issue 25, 2006, Pages 4190-4195

  D'Amico, Anthony V ^a   Loffredo, Marian ^a   Renshaw, Andrew A ^a   Loffredo, Brittany ^a   Chen, Ming Hui ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK; SURVIVAL; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33748672673     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.8239     Document Type: Article

References (24)

1. D'Amico AV, Chen M, Roehl K, et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135, 2005
2. Sengupta S, Myers RP, Slezak JM, et al: Preoperative prostate-specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174:2191-2196, 2005
3. Patel DA, Presti JC Jr, McNBeal JE, et al: Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23:6157-6162, 2005
4. D'Amico AV, Renshaw AA, Sussman B, et al: Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294:440-447, 2005
5. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360:103-106, 2002
6. Denham J, Steigler A, Lamb DS, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Tran-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005
7. D'Amico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004
8. Greene FL. Prostate, in Greene FL, Page DL, Fleming ID, et al (eds): AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002, pp 309-316
9. Lee AK, Levy LB, Cheung R, et al: Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63:456-462, 2005
10. D'Amico AV, Chen MH, Roehl K, et al: Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 23:4975-4979, 2005
11. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005
12. D'Amico AV, Moul J, Carroll P, et al: Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
13. the Veterans Administration Cooperative Urological Research Group.Gleason DF, Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology. Philadelphia, PA, Lea & Febiger, 1977, pp 171-187
14. Kutner MH, Nachtscheim CJ, Neter J, et al: Simple linear regression, in Kutner MH, Nachtscheim CJ, Neter J, et al (eds): Applied Linear Statistical Models (ed 5). New York, NY, McGraw-Hill/Irwin, 2005, pp 1-99
15. Agresti A: Two-way contingency tables, in Agresti A (ed): An Introduction to Categorical Data Analysis (ed 2). New York, NY, John Wiley & Sons, 2002, pp 16-52
16. Hollander M, Wolfe DA: The two sample location problem, in Hollander M, Wolfe DA (eds): Nonparametric Statistical Methods (ed 2). New York, NY, John Wiley & Sons, 1999, pp 106-140
17. Klein JP, Moeschberger ML: Semiparametric proportional hazards regression with fixed covariates, in Klein JP, Moeschberger ML (eds): Survival Analysis: Techniques for Censored and Truncated Data (ed 2). New York, NY, Springer, 2003, pp 243-293
18. Fine JP, Gray RJ: A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
19. Klein JP, Moeschberger ML. Regression Diagnostics, in Klein JP, Moeschberger ML (eds): Survival Analysis: Techniques for Censored and Truncated Data (ed 2). New York, NY, Springer, 2003, pp 353-392
20. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-500, 1958
21. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
22. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1998
23. Cox JD: Guidelines for PSA following radiation therapy: American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
24. Horwitz EM, Thames HD, Kuban DA, et al: Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 173:797-802, 2005